In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Integra Lifesciences (NASDAQ: IART), with a price target of $62. The company’s shares closed yesterday at $53.57.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 22.3% and a 60.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, OrthoPediatrics Corp, and Stryker Corporation.
Currently, the analyst consensus on Integra Lifesciences is a Moderate Buy with an average price target of $61, which is a 13.9% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.50 and a one-year low of $45.96. Currently, Integra Lifesciences has an average volume of 638.3K.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
